GENENTECH USA, INC - NEW AWARD FOR RANIBIZUMAB (LUCENTIS) SYRINGES WITH GENENTECH USA, INC. PERIOD OF PERFORMANCE IS 12/23/23 TO 12/22/24 WITH FOUR ONE-YEAR OPTIONS.
Key Details
Description
NEW AWARD FOR RANIBIZUMAB (LUCENTIS) SYRINGES WITH GENENTECH USA, INC. PERIOD OF PERFORMANCE IS 12/23/23 TO 12/22/24 WITH FOUR ONE-YEAR OPTIONS.
Context & Analysis
On Dec 17, 2025, Department of Veterans Affairs to GENENTECH USA, INC for new award for ranibizumab (lucentis) syringes with genentech usa, inc. period of performance is 12/23/23 to 12/22/24 with four one-year options.. The award is classified under NAICS 325412 — PHARMACEUTICAL PREPARATION MANUFACTURING and issued as a firm fixed price contract. Competition extent: full and open competition with 3 offers received. The procurement used a NO SET ASIDE USED. set-aside. This award is one of several similar procurements from Department of Veterans Affairs under NAICS 325412 — related awards are listed below.
Contractor Information
Similar Awards
EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2026 NOVEMBER
MCKESSON CORPORATION
$1.4B
EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2026 OCTOBER
MCKESSON CORPORATION
$1.2B
EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2026 DECEMBER
MCKESSON CORPORATION
$1.1B
EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2026 JANUARY
MCKESSON CORPORATION
$1.1B
LENALIDOMIDE FOR THE SALISBURY VAMC, CHARLOTTE HCC, AND KERNERSVILLE HCC.
EXELAN PHARMACEUTICALS INC
$5.1M
Stay Updated
Get notified about new opportunities matching your interests.